Charles River Laboratories International (CRL) Operating Leases (2019 - 2025)

Charles River Laboratories International's Operating Leases history runs 7 years deep, the most recent figure standing at $491.7 million for Q4 2025.

• In Q4 2025, Operating Leases rose 1.64% year-over-year to $491.7 million; the TTM figure through Dec 2025 stood at $491.7 million (up 1.64% YoY), while the FY2025 annual figure was $491.7 million, up 1.64% from the prior year.
• Operating Leases for Q4 2025 stood at $491.7 million, up from $443.2 million in the prior quarter.
• The five-year high for Operating Leases was $491.7 million in Q4 2025, with the low at $173.0 million in Q1 2021.
• The 5-year median for Operating Leases is $418.1 million (2023), against an average of $387.6 million.
• The sharpest annual moves came in 2021 and 2024: Operating Leases surged 84.07% in 2021, then retreated 0.04% in 2024.
• Charles River Laboratories International's Operating Leases stood at $286.2 million in 2021, then jumped by 52.41% to $436.3 million in 2022, then advanced by 8.68% to $474.1 million in 2023, then advanced by 2.03% to $483.8 million in 2024, then advanced by 1.64% to $491.7 million in 2025.
• Business Quant data shows CRL's Operating Leases at $491.7 million in Q4 2025, $443.2 million in Q3 2025, and $453.7 million in Q2 2025.